---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-063793"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T12:14:43.294756+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Traws Pharma submits Phase 2 protocols for bird flu and COVID drugs; requests FDA meeting

## Summary
- Submitted HREC Phase 2 protocol for tivoxavir marboxil (TXM) to treat H5N1 bird flu and seasonal influenza.
- Submitted Type D FDA meeting request to discuss accelerated approval for TXM under the Animal Rule.
- Submitted HREC Phase 2 protocol for ratutrelvir in acute COVID, including PAXLOVID-ineligible patients, with rebound and Long COVID assessments.
- Cash and equivalents of $15.9M as of March 31, 2025, expected to fund operations into Q1 2026.
- Continuing discussions with BARDA regarding strategic stockpile inclusion for TXM.

## SEC filing metadata
- accession: 0001104659-25-063793
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/0001104659-25-063793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925063793/tm2519404d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-063793
- JSON: https://secwatch.observer/filing/0001104659-25-063793.json
- Plain text: https://secwatch.observer/filing/0001104659-25-063793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.